Dr. Mims on FDA Approval of Ivosidenib in Patients With AML

Alice Mims, MD
Published: Friday, Jul 20, 2018



Alice Mims, MD, medical oncologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of the IDH1m inhibitor ivosidenib for the treatment of patients with acute myeloid leukemia (AML).
SELECTED
LANGUAGE


Alice Mims, MD, medical oncologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of the IDH1m inhibitor ivosidenib for the treatment of patients with acute myeloid leukemia (AML).



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x